Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461562 | 0.94 | ALDH1A1 (0.35) | ALDH1A1TSHRLMNAALOX5CHRNB2 | |
| SCHEMBL21680467 | 0.92 | L3MBTL1 (0.36) | ALDH1A1TSHRLMNAL3MBTL1KDM5A | |
| SCHEMBL25352553 | 0.92 | L3MBTL1 (0.36) | ALDH1A1TSHRLMNAL3MBTL1KDM5A | |
| SCHEMBL735688 | 0.86 | — | — | |
| SCHEMBL22205611 | 0.86 | LMNA (0.44) | ALDH1A1TSHRLMNAALOX5CHRNB2 | |
| SCHEMBL24703880 | 0.86 | ALDH1A1 (0.42) | ALDH1A1TSHRLMNAALOX5CHRNB2 | |
| SCHEMBL29991123 | 0.84 | ALDH1A1 (0.41) | ALDH1A1LMNAKDM5A | |
| SCHEMBL4019745 | 0.81 | PHF8 (0.39) | ALDH1A1TSHRLMNAALOX5MEN1 | |
| SCHEMBL30885012 | 0.81 | TSHR (0.62) | ALDH1A1TSHRLMNAL3MBTL1MEN1 | |
| SCHEMBL6541852 | 0.80 | CAMK2A (0.39) | ALDH1A1TSHRLMNAALOX5CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365585-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365585-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365585-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. | 2023-11-16 | — | — | US | disclosed |
| EP-4178965-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | Pfizer Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| CN-116075515-A | Benzodiazepine derivatives useful for the treatment of respiratory syncytial virus infection | 辉瑞大药厂 | 2023-05-05 | — | — | CN | disclosed |
| WO-2022008912-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | ReViral Limited (GB) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022008912-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | ReViral Limited (GB) | 2022-01-13 | — | — | WO | disclosed |
| EP-2935278-B1 | TRICYCLIC COMPOUNDS FOR INHIBITING THE CFTR CHANNEL | NOVARTIS AG (CH) | 2017-03-15 | — | — | EP | disclosed |
| US-9359381-B2 | Tricyclic compounds for inhibiting the CFTR channel | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| US-9359381-B2 | Tricyclic compounds for inhibiting the CFTR channel | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| US-8138175-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2321285-A1 | DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-2220055-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010012619-A1 | DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | WO | disclosed |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2009010429-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| EP-1107753-A1 | MULTIVALENT AGONISTS, PARTIAL AGONISTS, INVERSE AGONISTS AND ANTAGONISTS OF THE 5HT2 RECEPTORS | Advanced Medicine, Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-1999063996-A1 | MULTIVALENT AGONISTS, PARTIAL AGONISTS, INVERSE AGONISTS AND ANTAGONISTS OF THE 5HT2 RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365585-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | CNR1, SIGMAR1, CBR1 | ALDH1A1 2494/4885TSHR 156/4885LMNA 2309/4885 |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | ALDH1A1 2750/4885TSHR 522/4885LMNA 3760/4885 |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | ALDH1A1 2364/4885TSHR 435/4885LMNA 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.